A multicentre study to determine the in vitro efficacy of flomoxef against extended-spectrum beta-lactamase producing Escherichia coli in Malaysia
Document Type
Article
Publication Date
11-1-2023
Abstract
Background: The high burden of extended-spectrum beta-lactamase-producing (ESBL)-producing Enterobacterales worldwide, especially in the densely populated South East Asia poses a significant threat to the global transmission of antibiotic resistance. Molecular surveillance of ESBL-producing pathogens in this region is vital for understanding the local epidemiology, informing treatment choices, and addressing the regional and global implications of antibiotic resistance. Methods: Therefore, an inventory surveillance of the ESBL-Escherichia coli (ESBL-EC) isolates responsible for infections in Malaysian hospitals was conducted. Additionally, the in vitro efficacy of flomoxef and other established antibiotics against ESBL-EC was evaluated. Results: A total of 127 non-repetitive ESBL-EC strains isolated from clinical samples were collected during a multicentre study performed in five representative Malaysian hospitals. Of all the isolates, 33.9% were isolated from surgical site infections and 85.8% were hospital-acquired infections. High rates of resistance to cefotaxime (100%), cefepime (100%), aztreonam (100%) and trimethoprim-sulfamethoxazole (100%) were observed based on the broth microdilution test. Carbapenems remained the most effective antibiotics against the ESBL-EC, followed by flomoxef. Antibiotic resistance genes were identified by PCR. The blaCTX-M-1 was the most prevalent ESBL gene, with 28 isolates (22%) harbouring blaCTX-M-1 only, 27 isolates (21.3%) co-harbouring blaCTX-M-1 and blaTEM, and ten isolates (7.9%) co-harbouring blaCTX-M-1, blaTEM and blaSHV. A generalised linear model showed significant antibacterial activity of imipenem against different types of infection. Besides carbapenems, this study also demonstrated a satisfactory antibacterial activity of flomoxef (81.9%) on ESBL-EC, regardless of the types of ESBL genes.
Keywords
Extended-spectrum beta-lactamase (ESBL), Escherichia coli, Antimicrobial resistance, Flomoxef, Enterobacterales, Surgical site infection
Publication Title
PeerJ
Recommended Citation
Yap, Polly Soo Xi; Chong, Chun Wie; Ponnampalavanar, Sasheela; Ramli, Ramliza; Harun, Azian; Jamaluddin, Tengku Zetty Maztura Tengku; Khan, Anis Ahmed; Ngoi, Soo Tein; Lee, Yee Qing; Lau, Min Yi; Tan, Shiang Chiet; Kong, Zhi Xian; Woon, Jia Jie; Mak, Siew Thong; Jabar, Kartini Abdul; Karunakaran, Rina; Ismail, Zalina; Salleh, Sharifah Azura; Noor, Siti Suraiya Md; Masri, Siti Norbaya; Taib, Niazlin Mohd; Jasni, Azmiza Syawani; Tee, Loong Hua; Leong, Kin Chong; Lim, Victor Kok Eow; Abu Bakar, Sazaly; and Teh, Cindy Shuan Ju, "A multicentre study to determine the in vitro efficacy of flomoxef against extended-spectrum beta-lactamase producing Escherichia coli in Malaysia" (2023). Research Publications (2021 to 2025). 3616.
https://knova.um.edu.my/research_publications_2021_2025/3616
Divisions
anaesthesiology,medbio,medicinedept,tidrec
Funders
Ministry of Education, Malaysia [Grant no. TRGS/1/2020/UM/02/2/2],Shionogi Singapore Pte. Ltd. [Grant no. IF015-2018]
Volume
11
Publisher
PeerJ
Publisher Location
341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND